Evidence map›Paper›PMID 39985091›Full record

ArticleCancer imaging : the official publication of the International Cancer Imaging Society2025

Total lesion glycolysis of primary tumor and lymphnodes is a strong predictor for development of distant metastases in oropharyngeal carcinoma patients with independent validation in automatically delineated lesions.

Sebastian Zschaeck, Marina Hajiyianni, Patrick Hausmann, Pavel Nikulin, Emily Kukuk, Christian Furth, Paulina Cegla, Elia Lombardo, Joanna Kazmierska, Adrien Holzgreve and 11 more

Erratum issuedAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer imaging : the official publication of the International Cancer Imaging Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors.

Sebastian Zschaeck *Department of Radiation Oncology, Charité- Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Augustenburger Platz 1, 13353, Berlin, Germany. Sebastian.Zschaeck@charite.de.ORCID http://orcid.org/0000-0003-3109-0662
Marina Hajiyianni *Department of Radiation Oncology, Charité- Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Augustenburger Platz 1, 13353, Berlin, Germany.
Patrick HausmannDepartment of Radiation Oncology, Charité- Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Augustenburger Platz 1, 13353, Berlin, Germany.
Pavel NikulinInstitute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.
Emily KukukDepartment of Radiation Oncology, Charité- Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Augustenburger Platz 1, 13353, Berlin, Germany.
Christian FurthDepartment of Nuclear Medicine, Charité Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin Institute of Health, Berlin, Germany.
Paulina CeglaDepartment of Nuclear Medicine, Greater Poland Cancer Centre, Poznan, Poland.
Elia LombardoDepartment of Radiation Oncology, LMU University Hospital, LMU Munich, Munich, Germany.
Joanna KazmierskaElectroradiology Department, University of Medical Sciences, Poznan, Poland.
Adrien HolzgreveDepartment of Nuclear Medicine, LMU University Hospital, LMU Munich, Munich, Germany.
Iosif StrouthosDepartment of Radiation Oncology, German Oncology Center, European University Cyprus, Limassol, Cyprus.
Carmen StrombergerDepartment of Radiation Oncology, Charité- Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Augustenburger Platz 1, 13353, Berlin, Germany.
Claus BelkaDepartment of Radiation Oncology, LMU University Hospital, LMU Munich, Munich, Germany.
Michael BaumannOncoRay- National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden- Rossendorf, Dresden, Germany.
Mechthild KrauseDepartment of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
Guillaume LandryDepartment of Radiation Oncology, LMU University Hospital, LMU Munich, Munich, Germany.
Witold CholewinskiDepartment of Nuclear Medicine, Greater Poland Cancer Centre, Poznan, Poland.
Jorg KotzerkeDepartment of Nuclear Medicine, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
Daniel ZipsDepartment of Radiation Oncology, Charité- Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Augustenburger Platz 1, 13353, Berlin, Germany.
Jörg van den HoffInstitute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.
Frank HofheinzInstitute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOropharyngeal carcinomas are characterized by an increasing incidence and a relatively good prognosis. Nonetheless, a considerable number of patients develops metachronous distant metastases; identification of these patients is an urgent medical need.

methodsThis is a retrospective multicenter evaluation of 431 patients. All patients underwent [

resultsIn the explorative group, univariate analyses revealed an association of metric MTV

conclusionsTLG

Indexed as

GlycolysisLymph NodesOropharyngeal NeoplasmsAdultAgedAged, 80 and overFemaleFluorodeoxyglucose F18HumansLymphatic MetastasisMaleMiddle AgedNeoplasm MetastasisPositron-Emission TomographyPrognosisRadiopharmaceuticalsFluorodeoxyglucose F18RadiopharmaceuticalsFluorodeoxyglucose positron emission tomographyHead and neck squamous cell carcinomaOropharynx cancerTotal lesion glycolysis

Identifiers

PMID39985091
PMCPMC11844016

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.